News Archive Archives - Page 3 of 8

Probiodrug to Present at the 1st Meeting of The Society for CSF analysis and Clinical Neurochemistry

HALLE/SAALE, Germany, 11 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces today that two […]

Probiodrug AG to Publish its First Quarter 2016 Business Update on May 12, 2016

HALLE/SAALE, Germany, 4 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its first […]

Probiodrug to Attend and Present at European Conferences in May 2016

HALLE/SAALE, Germany, 3 May 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]

Probiodrug to hold its Ordinary General Meeting of Shareholders on May 19, 2016

HALLE/SAALE, Germany, 05 April 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour to […]

Probiodrug announces results of chronic toxicology studies with PQ912, its ‘first in class’ Glutaminyl Cyclase (QC) inhibitor for the treatment of Alzheimer’s disease

Favourable results enable longer patient treatment HALLE/SAALE, Germany, 04 April 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat […]

Probiodrug to Present and Attend European Conferences in April 2016

HALLE/SAALE, Germany, 31 March 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]

Probiodrug Appoints Mark Booth as Chief Business Officer

Expands Management Board with Senior Hire HALLE/SAALE, Germany, 23 March 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat […]

Probiodrug reports full year 2015 financial results

Phase 2a study of novel treatment for Alzheimer’s disease initiated Phase 1 PQ912 data, a first in class Glutaminyl Cyclase (QC) inhibitor for the treatment of […]

Probiodrug’s pGlu-Abeta Approaches being presented at 14th AAT Symposium on Advances in Alzheimer Therapy

The Symposium will be held from 9 to12 March 2016 at the Athens Hilton in Athens, Greece HALLE/SAALE, Germany, 09 March 2016 – Probiodrug AG (Euronext […]

Probiodrug AG to Publish its Full Year 2015 Results on March 15, 2016

HALLE/SAALE, Germany, 7 March 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Full Year […]

Probiodrug to Attend and Present at European Conferences in March 2016

HALLE/SAALE, Germany, 22 February 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]

Probiodrug to Attend and Present at European and US Conferences in February 2016

HALLE/SAALE, Germany, 28 January 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Dr Konrad Glund, […]